D-0295-2025 Class II Ongoing
FDA drug recall D-0295-2025 was initiated by QuVa Pharma, Inc. on Mar 6, 2025 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 2, 2025
- Initiation Date
- Mar 6, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.1% Bupivacaine HCl 100 mg/100 mL (1 mg/mL), 100 ml in NS Yellow CADD FSFF, Injection for Epidural Use (Not intended For IV Use), Compounded, For Institutional or Office Use Only, QuVa Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, Tx 77478. NDC: 70092-1255-75
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
U.S. Nationwide
Code information
Lots: 10140259, 10140539, 10140687, 10140688; Exp 04/24/2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0295-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026